Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.

Linda DirvenJammbe Z MusoroCorneel CoensJaap C ReijneveldMartin J B TaphoornFlorien W BoeleMogens GroenvoldMartin J van den BentRoger StuppGalina VelikovaKim CocksMirjam A G SprangersMadeleine T KingHans-Henning FlechtnerAndrew Bottomley

Published in: Neuro-oncology (2021)

MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 results from glioma trials.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis